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BRCA1 positively regulates FOXO3 expression by restricting
FOXO3 gene methylation and epigenetic silencing through
targeting EZH2 in breast cancer
C Gong1,2, S Yao1, AR Gomes1, EPS Man2, HJ Lee3, G Gong3, S Chang4, S-B Kim5, K Fujino1, S-W Kim6, SK Park7, JW Lee8, MH Lee9,
KOHBRA study group, US Khoo2 and EW-F Lam1
BRCA1 mutation or depletion correlates with basal-like phenotype and poor prognosis in breast cancer but the underlying reason
remains elusive. RNA and protein analysis of a panel of breast cancer cell lines revealed that BRCA1 deficiency is associated with
downregulation of the expression of the pleiotropic tumour suppressor FOXO3. Knockdown of BRCA1 by small interfering RNA
(siRNA) resulted in downregulation of FOXO3 expression in the BRCA1-competent MCF-7, whereas expression of BRCA1 restored
FOXO3 expression in BRCA1-defective HCC70 and MDA-MB-468 cells, suggesting a role of BRCA1 in the control of FOXO3
expression. Treatment of HCC70 and MDA-MB-468 cells with either the DNA methylation inhibitor 5-aza-2'-deoxycitydine, the
N-methyltransferase enhancer of zeste homologue 2 (EZH2) inhibitor GSK126 or EZH2 siRNA induced FOXO3 mRNA and protein
expression, but had no effect on the BRCA1-competent MCF-7 cells. Chromatin immunoprecipitation (ChIP) analysis demonstrated
that BRCA1, EZH2, DNMT1/3a/b and histone H3 lysine 27 trimethylation (H3K27me3) are recruited to the endogenous FOXO3
promoter, further advocating that these proteins interact to modulate FOXO3 methylation and expression. In addition, ChIP results
also revealed that BRCA1 depletion promoted the recruitment of the DNA methyltransferases DNMT1/3a/3b and the enrichment
of the EZH2-mediated transcriptional repressive epigenetic marks H3K27me3 on the FOXO3 promoter. Methylated DNA
immunoprecipitation assays also confirmed increased CpG methylation of the FOXO3 gene on BRCA1 depletion. Analysis of the
global gene methylation profiles of a cohort of 33 familial breast tumours revealed that FOXO3 promoter methylation is significantly
associated with BRCA1 mutation. Furthermore, immunohistochemistry further suggested that FOXO3 expression was
significantly associated with BRCA1 status in EZH2-positive breast cancer. Consistently, high FOXO3 and EZH2 mRNA levels were
significantly associated with good and poor prognosis in breast cancer, respectively. Together, these data suggest that BRCA1 can
prevent and reverse FOXO3 suppression via inhibiting EZH2 and, consequently, its ability to recruit the transcriptional repressive
H3K27me3 histone marks and the DNA methylases DNMT1/3a/3b, to induce DNA methylation and gene silencing on the FOXO3
promoter.
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INTRODUCTION
Breast cancer is the most common type of cancer among women
worldwide. BRCA1 is a multifunctional tumour suppressor, which has
a key role in mammary tumorigenesis. BRCA1 dysregulation and/or
mutation are closely associated with a higher risk of breast cancer in
familial cases. Accordingly, reduced BRCA1 expression or mutation
has been frequently reported in sporadic breast cancer.1,2 BRCA1
silencing or mutation is also associated with basal-type breast
cancer phenotype in which the tumour cells express no estrogen
receptor (ER), progesterone receptor (PR) nor human epidermal
growth factor receptor 2 (HER2) receptor, high p53 mutation and
poor prognosis.3 The mechanisms linking BRCA1 loss/mutation to
tumorigenesis are not clearly understood. Inactivation of BRCA1 has
been shown to induce malignant cell behaviour including
accelerated cell proliferation, enhanced anchorage-independent
growth and suppressed expression of proliferative inhibitors
p21Waf1/Cip1 and p27Kip1.4 In this context, BRCA1 can transcriptionally
regulate p27Kip1 in cooperation with FOXA1.5,6 BRCA1 also regulates
expression of Survivin, an inhibitor of cell division and apoptosis,7
through regulating the expression of the NAD+-dependent deace-
tylase sirtuin-1.8 In addition, it has been reported that BRCA1 can
negatively regulate phosphoinositide 3-kinase/AKT pathway by
inducing AKT ubiquitination and degradation, resulting in FOXO3
hypophosphorylation and induction of FOXO3 activity.9
The transcription factor FOXO3 is a member of the Forkhead
box (FOX) protein family and a well-established tumour
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suppressor, which transcriptionally regulates genes that are
important in a myriad of cellular processes such as cell cycle
progression,10 apoptosis,11 angiogenesis12 and chemotherapeutic
drug response.13 High FOXO3 expression has been reported to be
associated with low histological grades, low tumour stages, lymph
node negativity and better survival in breast cancer patients,14
and has been shown to suppress the oestrogen-dependent breast
cancer tumorigenesis in vivo.15 In addition, FOXO3 is also the
central mediator of the pro-proliferative phosphoinositide
3-kinase/AKT signalling pathway in which AKT phosphorylation
causes the inactivation, nuclear exclusion and subsequently
degradation of FOXO3.16 Other kinases such as IκB kinase17 and
extracellular signal-regulated kinase18 can also phosphorylate and
downregulate FOXO3 activity in a similar manner, to promote cell
proliferation and tumorigenesis.
EZH2 (enhancer of zeste homologue 2) is the enzymatic
subunit of the polycomb-repressive complex 2 (PRC2) and a
methyltransferase that specifically catalyses the addition of methyl
groups to histone H3 at lysine 27 (H3K27). Trimethylation of H3K27
(H3K27me3) serves as an epigenetic code for further recruitment
of other polycomb complexes, DNA methyltransferases (DNMTs)
and histone deacetylases, leading to chromatin condensation and
transcription suppression.19 EZH2 overexpression is associated
with metastasis and poor survival in breast cancer patients.20 It has
been shown that growth of Brca1-deficient mouse mammary
tumours is dependent on EZH2 expression.21 Interestingly, BRCA1
can bind directly to EZH2 and negatively regulate its functions in
both mouse embryonic stem cells and human breast cancer
cells.22 In the current study, we sought to bridge BRCA1 and
FOXO3, the two core tumour suppressors in breast cancer,
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Figure 1. BRCA1 status correlates with FOXO3 expression in breast cancer cell lines. (a) Western blotting and (b) qRT–PCR analysis was
performed on a panel of five different breast cancer cell lines including the luminal-type cell line MCF-7, which expresses wild-type BRCA1,
basal-type cell lines HCC70, MDA-MB-231, MDA-MB-468 and MDA-MB-436, expressing either low or mutated BRCA1. (a) The expression of
BRCA1, FOXO3, EZH2, ERα, GATA3 and Tubulin was examined by western blotting. (b) The experiments were repeated three times
independently and qRT–PCR results were normalized against L19 mRNA levels and the results presented as bars representing mean± s.d.
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focusing on the role of BRCA1 in regulating FOXO3 expression,
and to delineate the regulatory mechanism involved.
RESULTS
Correlation between BRCA1 and FOXO3 expression in breast
cancer cell lines
To investigate the relationship between BRCA1 and FOXO3
expression, western blot analysis was performed on a panel of
five breast cancer cell lines, which include the luminal-type MCF-7
cells with wild-type-competent BRCA1 and the basal-type lines
HCC70, MDA-MB-231, MDA-MB-436 and MDA-MB-468 expressing
either low or mutated BRCA1. Luminal markers, ERα and GATA3
were only expressed in MCF-7 but not in the basal-type breast
cancer lines. Despite the great heterogeneity among the cell lines,
there was strong correlation between the expression of wild-type
BRCA1 and FOXO3. There was significant higher FOXO3 expres-
sion at both the mRNA and protein levels in MCF-7 compared with
the basal-type cell lines (Figures 1a and b). Consistent with our
previous results,23 the Polycomb protein EZH2 was found to be
ubiquitously expressed in all five cell lines.
BRCA1 regulates FOXO3 expression
The correlation between BRCA1 and FOXO3 expression in the
panel of breast cancer cell lines led us hypothesize that BRCA1
regulates FOXO3 expression. To test this conjecture, BRCA1 was
silenced in MCF-7 cells using a small interfering RNA (siRNA) pool.
BRCA1 depletion resulted in a significant reduction in FOXO3
expression at both the protein and mRNA levels in MCF-7 cells
(Figure 2a) compared with the non-silencing control and the mock
transfected MCF-7 cells, supporting the notion that BRCA1
regulates FOXO3 expression. Consistently, overexpression of
wild-type, but not a C61G mutant, BRCA1 in basal-type cell
lines HCC70 (low BRCA1) and MDA-MB-468 (mutated BRCA1)
significantly enhanced the expression of FOXO3 at both the
protein and mRNA levels (Figures 2b and c, respectively). Taken
together, these results suggest that BRCA1 regulates FOXO3
expression at least in part at the transcriptional level.
5′-Aza-dC treatment induces FOXO3 expression in basal-type cell
lines
To investigate further the relevance of FOXO3 methylation in
repressing FOXO3 expression in basal breast cancer, the
basal-type cell lines HCC70 and MDA-MB-468, and the luminal-
type cell line MCF-7 were treated with different amounts of
5′-aza-dC (0, 1 and 5 μM) for 72 h, and BRCA1, FOXO3 and EZH2
expression levels examined by both western blotting and
quantitative reverse-transcriptase PCR (qRT–PCR). In HCC70,
FOXO3 mRNA and protein expression was significantly induced
after treatment with 1 and 5 μM of 5′-aza-dC for 72 h (both
Po0.05, Students’ t-test) (Figure 3a). In agreement, the FOXO3
expression was also increased after 5′-aza-dC treatment in MDA-
MB-468 cells (Figure 3b). On the contrary, treatment of the luminal
MCF-7 cells with 5′-aza-dC did not alter the expression levels of
FOXO3 (Figure 3c), indicating that FOXO3 expression is repressed
by DNA methylation in the absence of BRCA1. Collectively, these
data provide evidence that FOXO3 is methylated in basal subtype
breast cancers, where BRCA1 is either mutated or depleted,
highlighting the importance of BRCA1 in promoting FOXO3
expression through suppressing FOXO3 methylation in luminal
breast cancers.
Inhibition or depletion of EZH2 induces FOXO3 expression
We next explored the mechanism by which BRCA1 negatively
regulates FOXO3 methylation and the cofactors involved. A
previous study showed that BRCA1 interacts with EZH2 to inhibit
its repression and the H3K27me3 on genes targeted by the PRC2
repressive complex in mouse embryonic stem and human breast
cancer cells.22 We also showed recently that BRCA1 inhibits
promoter methylation and chromatin silencing of FOXA1 through
binding to EZH2.23 These findings raised the possibility that BRCA1
promotes FOXO3 expression through inhibiting EZH2 activity and
histone lysine 27 trimethylation. To test this idea, we treated
HCC70, MDA-MB-468 and MCF7 with GSK126, a highly selective
S-adenosyl-methionine-competitive inhibitor of EZH2 methyltrans-
ferase activity,24 and studied its effect on FOX3a expression. The
results showed that FOXO3 transcript and protein levels were
significantly induced by treatment with 5 μM of GSK126 for 72 h in
both the BRCA1-low basal-type cell HCC70 and BRCA1-mutated
basal-type cell MDA-MB-468 (Po0.05, Students’ t-test; Figure 4a
and b, respectively). In comparison, FOXO3 expression was not
affected by GSK126 in MCF7, which expresses high levels of wild-
type BRCA1 (Figure 4c). This result suggests that EZH2 is involved
in the repression of FOXO3 expression in the BRCA1-deficient or
-mutated cells but not in the BRCA1-competent cells. To further
confirm this finding, EZH2 was depleted in the HCC70 and MCF7
cells. The knockdown efficiency of EZH2 after 72 h was confirmed
by western blotting and qRT–PCR analysis. It was found that in
HCC70 cells, EZH2 depletion significantly induced FOXO3 expres-
sion both at the protein and mRNA levels when compared with
the non-silencing controls and the mock-transfected cells
(Figure 5a). However, in MCF-7 cells, EZH2 knockdown did not
affect FOXO3 expression (Figure 5b). Together, these data support
the idea that EZH2 negatively regulates FOXO3 transcription in
BRCA1-deficient breast cancer cells, whereas this EZH2 activity is
repressed by BRCA1 in BRCA1-competent cells.
FOXO3 promoter is enriched with EZH2 and H3K27me3 in
basal-type cells
Hitherto, our data indicated that BRCA1 inhibits EZH2 activity to
suppress the silencing of FOXO3. Previously, EZH2 has been shown
to cause H3K27me3 and DNA methylation at target genes through
recruiting DNMTs including DNMT1, DNMT3a and DNMT3b.25
Collectively, these and our present findings suggest the possibility
that EZH2 induces H3K27 trimethylation, which facilitates the
recruitment of DNMTs to promote DNA methylation and silencing
at the FOXO3 promoter in BRCA1-deficient cells. To test this
conjecture, we next investigated by chromatin immunoprecipita-
tion (ChIP) analysis the occupancy of the human FOXO3 promoter
region by BRCA1, EZH2, DNMT1, DNMT3a, DNMT3b and
H3K27me3 in the BRCA1-low HCC70 cells and BRCA1-mutated
MDA-MB-468 cells, as well as the BRCA1-competent MCF-7 cells.
In silico analysis of the transcription factor ChIP sequencing data
sets in HepG2 cells available in the ENCODE project repository26
identified putative binding regions for EZH2, BRCA1 and
H3K27me3, respectively, located on the FOXO3 promoter
(Figure 6). ChIP analysis was performed using primers designed
to amplify across the EZH2-, BRCA1- and H3K27me3-binding
regions upstream of the two transcription start sites on the FOXO3
promoter (Figure 6). qRT–PCR results showed that the FOXO3
promoter was enriched for BRCA1, EZH2 and H3K27me3 in the
BRCA1-deficient HCC70 (Figure 7a) and MDA-MB-468 (Figure 7b)
cells. In contrast, although both BRCA1 and EZH2 bound to the
FOXO3 promoter, there was no significant enrichment of
H3K27me3 in the BRCA1-competent MCF-7 cells (Figure 7c). These
results further support the notion that BRCA1 inhibits EZH2 to
repress H3K27me3 on the FOXO3 promoter. Consistently, ChIP
analysis also revealed that DNMT1, DNMT3a and DNMT3b
were enriched on FOXO3 promoter in HCC70 (Figure 8a) and
MDA-MB-468 (Figure 8b) but not in MCF-7 cells (Figure 8c). This
indicates that DNA binding does not solely determine BRCA1
activity, which are regulated by multiple posttranslational
mechanisms and its mutation status. In agreement, although
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both HCC70 and MCF-7 express wild-type BRCA1 and MDA-
MB-468 has mutated BRCA1, MCF-7 is a luminal, while HCC70 and
MDA-MB-468 are triple-negative breast cancer cell lines, which are
more similar phenotypically to BRCA1-negative cells.
BRCA1 represses the deposit of H3K27me3 and DNMTs to FOXO3
promoter
To establish further the role of BRCA1 in regulating the EZH2-
induced deposition of histone mark H3K27me3 on the FOXO3
promoter, BRCA1 was silenced using siRNA in MCF-7 cells, which
express wild-type BRCA1. ChIP–qPCR analysis revealed that when
compared with the non-silencing control siRNA-transfected
controls, depletion of BRCA1 induced an accumulation of
H3K27me3 marks on the FOXO3 promoter, as detected by all
four pairs of BRCA1/EZH2 primers (Figure 9a). Similarly, BRCA1
silencing also promoted the recruitment of DNMT1, DNMT3a and
DNMT3b onto the FOXO3 promoter, as detected by all four primer
pairs (Figure 9b). These results are in line with our hypothesis that
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Figure 2. BRCA1 regulates FOXO3 expression in breast cancer cells. (a) BRCA1 depletion results in a significant reduction in FOXO3 expression
levels in MCF-7 cells. Western blotting and qRT–PCR analysis was performed on MCF-7 cells transfected with BRCA1-specific siRNA pool or
non-silencing control (NSC) siRNA pool for 48 h. FOXO3 expression was observed to be downregulated both at the protein and mRNA levels.
For qRT–PCR analysis, the experiments were repeated three times independently and results normalized against L19 mRNA levels and
expressed as mean± s.d. *P⩽ 0.05, **P⩽ 0.01 and ***P⩽ 0.001 by Students’ t-test. (b and c) BRCA1 overexpression induces FOXO3 expression
in the BRCA1-deficient HCC70 and MDA-MB-468 cell lines. (b) HCC70 and (c) MDA-MB-468 cells were transfected with the empty expression
vector pcDNA3 or pcDNA3-HA-BRCA1 wild-type or mutant expression vector. Total protein was extracted from whole-cell lysates were
extracted from these cells and analysed by western blotting with the indicated antibodies. FOXO3 and BRCA1 mRNA levels were also analysed
by qRT–PCR, with results normalized with L19 mRNA levels. All qRT–PCR results presented as bars representing mean± s.d of three
independent experiments in triplicates. *P⩽ 0.05, **P⩽ 0.01and ***P⩽ 0.001; NS not significant by Students’ t-test (two-tailed).
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BRCA1 negatively regulates EZH2 to induce H3K27 trimethylation
and the recruitment of DNMT1/3a/3b on the FOXO3 promoter and
gene silencing.
BRCA1 represses FOXO3 promoter methylation in breast cancer
Our data demonstrated that BRCA1 suppresses the ability of
EZH2 to recruit DNMT1/3a/3b to the FOXO3 promoter, to repress
FOXO3 expression. We next asked whether BRCA1 also represses
methylation of the FOXO3 promoter and used methylated DNA
immunoprecipitation to study the methylation status of the
FOXO3 promoter in the absence or presence of BRCA1 or EZH2
depletion in the BRCA1 wild-type MCF-7 cells (Figure 9c). Our
qRT–PCR showed that the levels of CpG methylation of FOXO3
genes increased on depletion of BRCA1 using siRNA, suggesting
that BRCA1 represses the FOXO3 promoter methylation and
silencing. Notably, EZH2 depletion did not have a significant effect
on FOXO3 promoter methylation, probably due to the fact that the
existing EZH2 is repressed by BRCA1 (Figure 9c).
BRCA1 suppresses cell proliferation at least partially through FOXO3
To establish the functional significance of BRCA1–FOXO3
regulatory axis in breast cancer, we evaluated whether the
anti-proliferative function of BRCA1 is mediated through FOXO3.
To this end, HCC70 cells were transfected with either FOXO3 siRNA
or non-silencing control siRNA together with the BRCA1 expres-
sion vector or the control empty vector (pcDNA3) (Supplementary
Figure S1). Consistent with their tumour suppressor functions,
FOXO3 depletion by siRNA accelerated cell proliferation when
compared with the control cells transfected with non-silencing
control siRNA and empty vector, whereas BRCA1 overexpression
suppressed the cell proliferation (Supplementary Figure S1).
Importantly, BRCA1 overexpression failed to effectively suppress
cell proliferation when FOXO3 was depleted by siRNA, in particular
at day 1. These results suggest that anti-proliferative function of
BRCA1 was achieved, at least partially, through FOXO3.
FOXO3 is hypermethylated and downregulated in BRCA1-mutated
breast tumours
Having established that BRCA1 positively regulates FOXO3
expression through inhibiting the ability of EZH2 to mediate
FOXO3 methylation and silencing in human breast cancer cells, we
next examined the association between FOXO3 methylation and
BRCA1 mutation status in a methylated DNA immunoprecipitation
data set from familial breast tumour samples collected by
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Figure 3. 5′-Aza-dC treatment induces FOXO3 expression in basal-type cell lines. The basal type cell lines (a) HCC70 and (b) MDA-MB-468, as
well as the luminal (c) MCF-7 cells were treated with 0, 1 and 5 μM of 5′-aza-dC for 72 h with culture medium changed every day. Total protein
was extracted from these cells and analysed by western blotting with the indicated antibodies. In parallel, total RNA was also extracted
and expression of BRCA1, EZH2 and FOXO3 mRNA was analysed by qRT–PCR. The experiments were repeated three times independently and
qRT–PCR results were normalized against L19 mRNA levels and the results expressed as mean± s.d. *P⩽ 0.05 and **P⩽ 0.001; NS, not
significant by Students’ t-test.
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kConFab (The Kathleen Cuningham Foundation Consortium for
Research into Familial Breast Cancer, Melbourne, Australia).27
There are 33 samples in the cohort, 11 of which harbour the
BRCA1 mutation. Statistical analysis of the methylation profiles
of FOXO3 promoter in these familial breast cancers revealed
that FOXO3 methylation levels were significantly higher in
BRCA1-mutated tumours, compared with BRCA2-, BRCAx- and
BRCA2/x-mutated tumours (P= 0.019, P= 0.053 and P= 0.026,
respectively) (Figure 10a). In concordance, analysis of FOXO3
and EZH2 transcript levels in a previously published breast cancer
cohort (3554 breast cancer patients)28 revealed that low FOXO3
and high EZH2 mRNA expression levels are very significantly
associated with poor survival (Po0.033 and P= 3.8 × 10− 11,
respectively, for overall survival, Kaplan–Meier analysis
(Figure 10b). The association of both FOXO3 and EZH2 mRNA
levels in survival analyses provides further evidence for the
involvement of both genes in breast cancer progression.
To further affirm our results, we also investigated the correlation
between BRCA1 mutation status and FOXO3 protein expression
levels in human samples by immunohistochemical staining on
tissue microarray constructed from 308 Korean breast cancer
cases with known BRCA1 status (Figure 11a). The representative
images of the immunohistochemical staining of BRCA1-mutated,
BRCA2-mutated and wild-type samples are shown (Figure 11b). It
was found that, although not statistically significant, the mean
FOXO3 protein expression levels were lower in BRCA1-mutated
samples in comparison with BRCA2-mutated, non-mutated or
non-BRCA1-mutated (that is, both BRCA2-mutated and wild-type
samples) (Figure 12a, Mann–Whiney U-rank test, P= 0.124,
P= 0.344 and P= 0.19, respectively). As EZH2 could also affect
FOXO3 expression, especially in BRCA1-mutated cells, we there-
fore investigated the correlations between FOXO3 expression and
BRCA mutation status in samples adjusted for their EZH2
expression levels. As shown in Figure 11b, EZH2 was expressed
in both the cytoplasm and the nucleus. The expression levels of
EZH2 in the cytoplasm were similar among all the samples with
almost all the cell cytoplasm showing intermediate intensity,
whereas the nuclear EZH2 expression varied between samples.
Moreover, EZH2 is mainly functionally active in the nucleus to
catalyse methylation of H3K27 and, therefore, only nuclear EZH2
expression was taken into account when analysing the data. In
patients who expressed low nuclear EZH2 (using median score as
cutoff), there was no significant difference in terms of FOXO3
expression levels between BRCA1 and BRCA2-mutated samples,
between BRCA1 and wild-type samples, and between BRCA1 and
non-BRCA1-mutated samples (Figure 12b, Mann–Whitney U-rank
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Figure 4. Inhibition of EZH2 induced FOXO3 expression in basal-type cell lines. The basal type cell lines (a) HCC70 and (b) MDA-MB-468, as well
as the luminal (c) MCF-7 cells were treated with 0, 1 and 5 μM of the EZH2 inhibitor GSK126 for 72 h with culture medium changed every day.
Total protein was extracted from these cells and analysed by western blotting with the indicated antibodies. In parallel, total RNA was also
extracted and expression of BRCA1, EZH2 and FOXO3 mRNA was analysed by qRT–PCR. The experiments were repeated three times
independently and qRT–PCR results were normalized against L19 mRNA levels and the results expressed as mean± s.d. *P⩽ 0.05 and
**P⩽ 0.001; NS, not significant Students’ t-test.
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test, P= 0.072, P= 0.507 and P= 0.21, respectively). In comparison,
in patients who expressed high nuclear EZH2, FOXO3 expression
was significantly lower in BRCA1-mutated samples when compar-
ing with BRCA2-mutated samples, and with non-BRCA1-mutated
samples (Figure 12c, Mann–Whitney U-rank test, P= 0.002 and
P= 0.017, respectively). These results indicate the regulation of
FOXO3 by BRCA1 via EZH2. Collectively, these in vivo data
provided strong evidence for the in vitro finding that BRCA1
positively regulates FOXO3 expression by suppressing the
function of EZH2, to promote FOXO3 methylation and silencing.
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Figure 5. Depletion of EZH2 induced FOXO3 expression in HCC70 but not in MCF-7 cells. Western blotting and qRT–PCR analysis was
performed on (a) HCC70 and (b) MCF-7 cells mock transfected or transfected with EZH2-specific siRNA pool or non-silencing control (NSC)
siRNA pool for 48 h. Depletion of EZH2 by siRNA in HCC70 significantly induced FOXO3 expression but did not affect FOXO3 expression in
MCF-7 cells. These experiments have been repeated three times and the representative western blottings were shown. qRT–PCR data were
expressed as mean± s.d; *Po0.05, **Po0.01 and ***Po0.001; NS, not significant.
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Figure 6. Schematic representation of the alignment of the binding profiles for EZH2, BRCA1 and H3K27me3, and the locations of the ChIP
primers with the human FOXO3 promoter. A schematic illustration of the human FOXO3 promoter region, showing the two transcription start
sites (Chr 6: 108,559,835- and Chr 6: 108,560,866-) (Top). ENCODE (the Encyclopedia of DNA Elements) project ChIP sequencing data of EZH2,
BRCA1 and H3K27me3 binding in the liver carcinoma HepG2 (ATCC Number HB-8065) cells were used for predicting global genome-binding
profiles for EZH2, BRCA1 and H3K27me3. The predicted binding profiles of EZH2, BRCA1 and H3K27me3 on the human FOXO3 promoter are
shown (below the FOXO3 promoter). The positions of the black boxes represent the amplicons of the designed ChIP primer pairs (primers 1–4;
further below). The predicted binding profiles of EZH2, BRCA1 and H3K27me3, and the locations of amplicons from the designed ChIP primer
pairs (primers 1–4) are aligned to the FOXO3 promoter.
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DISCUSSION
The breast cancer susceptibility protein BRCA1 is an important
tumour suppressor in breast cancer. Mutations in BRCA1
predispose women to a higher lifetime risk of breast and
ovarian cancer.29 BRCA1 is implicated in mammary epithelial
cell differentiation and its deficiency is often associated with
basal-like breast cancer subtype.30 Although it has been
reported that BRCA1 imposes its tumour suppressive role by
regulating DNA damage repair and cell cycle checkpoint,
the exact reason whereby BRCA1 deficiency or mutation causes
more aggressive breast cancer phenotype remains largely
unknown.
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Figure 7. H3K27me3 is only enriched on the FOXO3 promoter in the BRCA1-deficient HCC70 and MDA-MB-468 cells but not in the
BRCA1-competent MCF-7 cells, qRT–PCR analysis of immunoprecipitated chromatin for the recruitment of BRCA1, EZH2 and H3K27me3 to the
endogenous FOXO3 promoter in HCC70, MDA-MB-468 and MCF-7 cells. (a) In HCC70, the ChIP–qPCR results showed that BRCA1, EZH2 and
H3K27me3 were all recruited to the FOXO3 promoter albeit BRCA1 at low levels. (b) BRCA1 (C61G mutant), EZH2 and H3K27me3 were
recruited to the FOXO3 promoter in MDA-MB-468 cells as revealed ChIP–qPCR analysis. (c) In MCF-7, BRCA1 and EZH2 were associated with the
FOXO3 promoter but H3K27me3 was not. The results were normalized to the amount of Input and compared with the IgG-negative controls.
IgG (R), rabbit IgG-negative control; IgG (M), mouse IgG-negative control. These experiments were repeated three times independently and
the qRT–PCR results presented as mean± s.d. *Po0.05, **Po0.01 and ***Po0.001; NS, not significant by Student’s t-test (two-tailed).
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Figure 9. BRCA1 depletion causes the accumulation of H3K27me3, DNMT1/3a/3b and DNA methylation on the FOXO3 promoter in MCF-7
cells. BRCA1 was transiently knocked down using specific siRNA pool in MCF-7 for 48 h. (a) MCF-7 cells transfected with BRCA1 and non-
silencing control (NSC) siRNA pools independently were analysed for the accumulation of H3K27me3 on the endogenous FOXO3 promoter by
ChIP–qRT–PCR analysis. The results showed that despite the variable changes in EZH2 recruitment, there was always an increase in the
accumulation of H3K27me3 marks on BRCA1 depletion. (b) MCF-7 cells transfected with BRCA1 and NSC siRNA pools independently were
analysed for the recruitment of DNMT1/3a/3b to the endogenous FOXO3 promoter by ChIP–qRT–PCR analysis. The results revealed that BRCA1
knockdown culminated in an increase in DNMT1/3a/3b recruitment. (c) MCF-7 cells transfected with BRCA1 and NSC siRNA pools
independently were analysed for FOXO3 promoter methylation by methylated DNA immunoprecipitation (MeDIP) qRT–PCR analysis. Despite
the primers 2 and 4 consistently failed to generate reliable results, the results from primer sets 1 and 3 showed that BRCA1, but not EZH2,
knockdown significantly enhanced FOXO3 promoter methylation. The results were normalized to the amount of Input and compared with the
IgG-negative controls. These experiments were repeated three times independently and the qRT–PCR results presented as mean± s.d.
*Po0.05, **Po0.01 and ***Po0.001; NS, not significant by Student’s t-test (two-tailed).
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In this study, we show that BRCA1 prevents and reverses FOXO3
suppression through suppressing the PRC2 methyltransferase
EZH2. FOXO3 expression was restored in basal but not in BRCA1-
competent MCF-7 cells following treatment with 5′-aza-dC,
supporting our hypothesis that FOXO3 is silenced by hypermethy-
lation in the basal BRCA1-deficient cell lines. Our data also reveal
that FOXO3 gene expression is negatively regulated by EZH2 in
basal cell lines, where BRCA1 is downregulated or mutated, but
not in the BRCA1-competent MCF-7 cells, affirming that BRCA1
represses the ability of EZH2 to suppress FOXO3 expression.
Moreover, chemical inhibition or siRNA-mediated depletion of
EZH2 enhanced FOXO3 expression in basal cell lines and not in
MCF-7 cells, suggesting that in the presence of BRCA1, EZH2 is
functionally inactive and is unable to suppress FOXO3 expression.
Consistently, there has been evidence suggesting the regulation
of FOXO3 expression by DNA methylation. For example, FOXO3
expression is regulated by its DNA methylation status in mouse
embryonic fibroblasts31 and hypomethylating agents including
Azacytidine and Decitabine can restore FOXO3 in acute myeloid
leukaemia patients.32 FOXO3 has also been identified as one
of the target genes regulated by EZH2-H3K27me3-dependent
transcriptional network in hepatocellular carcinoma.33 On the
contrary, FOXO3 has also been reported to be a transcriptional
regulator of DNMT3b in lung cancer.34
EZH2, a key subunit in the PRC2, has been shown to
epigenetically suppress target gene expression through
modulating both histone and DNA methylation. Accordingly,
in addition to mediating the trimethylation of H3K27, an
epigenetic mark for transcriptional silencing, EZH2 also directly
recruits DNMTs, to induce DNA methylation and gene silencing. As
BRCA1 has been shown to be able to bind EZH2 and negatively
regulate PRC2 complex activity,22 and as we have previously
shown that both BRCA1 and DMNT3 bind to EZH2 but do not exist
in the same complexes in breast cancer cells,23 these lead us to
propose that BRCA1 can promote the transcription of FOXO3
indirectly through binding to EZH2 subunit of the PRC2 complex,
thereby restraining its methyltransferase activity. In agreement,
our ChIP assays showed that DNMT1/3a/3b and the transcriptional
repressive histone mark H3K27me3 are recruited to the promoter
region of FOXO3 in BRCA1-low and -mutated breast cancer cell
lines but not in BRCA1-competent MCF-7 cells. Furthermore,
depletion of BRCA1 by siRNA in MCF-7 induces the deposition of
H3K27me3 on the FOXO3 promoter.
These in vitro findings are further corroborated by the in vivo
correlation of BRCA1 mutation with FOXO3 promoter methylation
and protein expression. FOXO3 methylation levels were
significantly higher in BRCA1-mutated tumours compared with
BRCA2, BRCAx (non-BRCA1/2) and non-BRCA1-mutated (BRCA2/x)
tumours (Figure 12). More interestingly, in patients who expressed
low EZH2, there are no significant differences in FOXO3 protein
expression levels when comparing BRCA1-mutated samples
with BRCA2-mutated, wild-type or non-BRCA1-mutated samples.
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Figure 10. (a) FOXO3 gene promoter is hypermethylated in BRCA1 mutation tumours. Frequency of FOXO3 promoter methylation in clinical
samples with mutations in BRCA1, BRCA2 and BRCAx tumours was analysed using the kConFab database. In 33 familial breast tumour
samples, significant higher percentage of FOXO3 promoter methylation was found in BRCA1-mutated tumours compared with BRCA2- or
BRCAx-mutated tumour. Boxplots represent median (centre line), interquartile range (box) and 95th percentiles (whisker), and samples out
with this range are represented as points. FOXO3 methylation scores were significantly higher in BRCA1-mutated samples when compared
with BRCA2 or BRCAx (P= 0.019 and P= 0.053, respectively, Students’ t-test) or BRCA2/x (P= 0.026, Students’ t-test). (b) Prognostic significance
of FOXO3 and EZH2 mRNA in breast cancer. Examination of FOXO3 and EZH2 transcript expression in a previously published cohort
(3455 breast cancer patients)28 revealed that both low FOXO3 and high EZH2 mRNA expression levels are very significantly associated with
poor survival (P= 0.033 and P= 3.8 × 10− 1, respectively, for overall survival, Kaplan–Meier analysis). The significance of both FOXO3 and
EZH2in survival analyses provides further evidence for the involvement of both genes in breast cancer progression and drug response.
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However, there are statistically significant differences in FOXO3
expression levels between BRCA1-mutated and BRCA2-mutated or
non-BRCA1-mutated samples (Figure 12). These results indicate
that BRCA1 is not able to regulate FOXO3 expression when EZH2
expression or activity is depleted, suggesting EZH2 is a key
intermediate in the control of FOXO3 by BRCA1. In other words,
the role of BRCA1 in positively regulating FOXO3 expression is
mediated through EZH2, consistent with the previous in vitro
results showing that BRCA1 promotes FOXO3 expression through
relieving the suppressive function of EZH2.
FOXO3 is a bona fide pleiotropic tumour suppressor that
negatively regulates cell proliferation and cancer progression by
regulating the expression of genes involved in differentiation,
apoptosis, cell cycle regulation, oxidative stress response, DNA
damage repair, metastasis and angiogenesis.35 FOXO3 can also
antagonize functions of FOXM1, which is a potent oncogene that
has a central role in promoting cell proliferation, migration,
invasion, angiogenesis, stem cell renewal and DNA damage repair,
processes which contribute to cancer initiation, progression and
drug resistance.12,35 As a result, FOXO3 expression is a good
prognostic marker for breast cancer,14,36 except when it is
deregulated and resides constitutively in the nucleus.37 FOXO3
is also a molecular target of multiple clinically available or
potential anti-cancer therapeutics and, therefore, its deregulation
could culminate in drug resistance.38 Doxorubicin treatment could
cause the phosphorylation of FOXO3 by stress-activated p38
mitogen-activated protein kinase and subsequently nuclear
localization and activation of FOXO3.13 Another recent study
showed that low dose of metformin, which is the active
metabolite of a topoisomerase-1 inhibitor derivative, suppresses
breast and ovarian cancer growth both in vitro and in vivo in a
FOXO3-dependent manner.39 As FOXO3 is such an crucial tumour
suppressor and therapeutic drug target, it is pertinent to
appreciate how FOXO3 expression is regulated normally and also
deregulated in cancer. Past studies have reported that the FOXO3
is primarily regulated by multiple kinases that could phosphor-
ylate FOXO3, which subsequently lead to nuclear exclusion and
ubiquitination/degradation in the cytoplasm.35,40 This study
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Figure 11. Immunostaining pattern of FOXO3 expression in breast cancers with different BRCA mutation status. (a) BRCA mutation makeup of
tissue microarray constructed from 308 cases of Korean breast cancer samples. (b) Representative staining images of FOXO3 and EZH2
immunohistochemical staining of BRCA1-mutated, BRCA2-mutated or wild-type breast cancer samples. Images (original magnification, × 20);
insets (original magnification, × 100).
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reports a novel regulatory mechanism of FOXO3 by BRCA1 in
breast cancer where BRCA1 indirectly regulates FOXO3 expression
through interfering with EZH2-H3K27me3 deposition onto the
FOXO3 promoter and its DNA methylation. The finding that
overexpression of FOXO3 mRNA levels is a good prognostic factor
in breast cancer (Figure 10b) further supports the importance of
FOXO3 regulation at the transcriptional level in breast cancer
development.
This could be important in breast cancer progression and
contribute to the understanding of tumour suppressive role of
BRCA1. In agreement, our result also show that BRCA1 suppresses
proliferation of basal type breast cancer cell line HCC70, at least
partially through FOXO3, as depletion of FOXO3 by siRNA
compromised the cell proliferation suppression induced by BRCA1
overexpression. The results suggest that the tumour suppressive
role of BRCA1 is partially achieved by regulating FOXO3
expression in breast cancer. In line with our findings, recent
studies have suggested that FOXO3 expression is regulated by its
DNA methylation status in mouse embryonic fibroblasts31 and
hypomethylating agents can reactivate FOXO3 in acute myeloid
leukaemia.32 Consistently, another recent study has also identified
FOXO3 as one of the target genes controlled by the
EZH2-H3K27me3-dependent transcriptional network in hepato-
cellular carcinoma.33 In concordance, a recent Phase I/Ib trail of
olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated
breast or ovarian cancer has revealed that FOXO3 expression is
associated with responsiveness.41 Thus, clinically approved
inhibitors of DNMT1 and DNMT3a/b, such as 5-Azacytidine
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Figure 12. FOXO3 and EZH2 expression levels in breast cancers with different BRCA mutation. (a) Comparison of FOXO3 expression levels with
different BRCA mutation status by Mann–Whitney U-rank test using all samples. (b) Comparison of FOXO3 expression levels with different
BRCA mutation status using samples that express low levels of nuclear EZH2 by Mann–Whitney U-rank test. (c) Comparison of FOXO3
expression levels with different BRCA mutation status compared using samples that express high levels of nuclear EZH2 by Mann–Whitney
U-rank test.
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(azacitidine) and 5-azadeoxycytidine (decitabine)42,43, or small
molecule inhibitors of EZH2 activity, including GSK126 and DZNep
(3-deazaneplanocin),24,44 may be used to restore FOXO3, to
enhance the efficacy of chemotherapeutic drugs in BRCA1/2
mutation-associated breast or ovarian cancer. In addition, the
expression levels of FOXO3 and FOXA1 may also be useful
biomarkers to molecularly classify BRCA1-mutated breast cancers.
To summarize, the current study demonstrates that BRCA1
positively regulates FOXO3 expression through inhibiting the activity
of ESH2 in breast cancer, whereas depletion or mutation of BRCA1
would lead to restoration of the ability of EZH2 to recruit DNMT1/3a/
3b methyltransferases and H3K27me3 histone marks, to mediate
methylation and silencing of the FOXO3 gene. These findings
contribute to better understand the tumour suppressor role of
BRCA1 and the regulation of another tumour suppressor FOXO3 in
breast cancer, and suggest FOXO3 as a diagnostic marker and
therapeutic target for BRCA1-deficient basal-like breast cancer. Thus,
this study has potential important diagnostic and therapeutic
implications for BRCA1 functional deficient breast cancer.
MATERIALS AND METHODS
Cell culture
The human breast carcinoma cell lines MCF-7, MDA-MB-231, MDA-MB-436,
MDA-MB-468 and HCC70 originated from the American Type Culture
Collection ((LGC standards, Middlesex, UK) and were authenticated by
Cancer Research UK (London, UK). See also Supplementary Materials and
Methods.
FuGENE6 transfection
Cells were seeded into six-well plates or 150-mm dishes, to achieve ~ 60%
confluency before transfection. Plasmid DNA was transfected using
FuGENE 6 (Roche Diagnostics, West Sussex, UK) in a 3:1 ratio following
manufacturer’s instructions. The pcDNA3-HA-BRCA1 wild-type expression
plasmids have previously been described45 and were obtained from
Dr David M Livingston (Harvard Medical School, Boston, MA, USA). The
BRCA1 mutant used is the cancer-predisposing mutation C61G disrupts
homodimer formation in the NH2-terminal BRCA1 RING finger domain.
It was generated by site-directed mutagenesis (by Quickchange
Mutagenesis kit; #200521, Agilent Technologies LDA UK Limited,
Gangnam-gu, Seoul, Korea) from the BRCA1 wild-type expression vector.
Gene silencing with siRNAs
All siRNAs for the work were ON-TARGETplus SMARTpool siRNA purchased
from Dharmacon Thermo Scientific (Lafayette, CO, USA). The SMARTpool
siRNAs used in this study were: siBRCA1 (L-003461-00), siEZH2 (L-004218-
00), siFOXO3 (L-003007-00-) and the ON-TARGETplus Non-Targeting Pool
(D-001810-10). The Dharmacon SMARTpool siRNA consists of at least four
different target-validated siRNA species designed to increase target
specificity and to minimize off-target effects. All siRNA pools were
resuspended to 20 μM in 1 × siRNA buffer before use. siRNAs or non-
targeting controls were delivered into the cells seeded in six-well plates or
150-mm dishes by using Oligofectamine (Invitrogen, Paisley, UK) following
the manufacturer’s instruction. Cells were collected 72 h after transfection.
Western blot analysis
Cells were collected for western blot analysis as described.46 Protein
concentration was determined by BCA protein assay (Bio-Rad, Hemel
Hempstead, UK). Twenty micrograms of protein were separated by SDS–
polyacrylamide gel electrophoresis, transferred to nitrocellulose membrane
and hybridized with the following antibodies at 4 °C for overnight: BRCA1
(1:1000, Millipore; 07-434, Watford, UK)23, EZH2 (1:1000, Diagenode,
Seraing/Ougrée, Belgium; C15410039), ERα (1:1000, Santa-Cruz, Insight
Biotechnology Ltd, Wembley, UK; sc-7207), β-tubulin (1:1000, Santa-Cruz);
FOXO3 (1:3000, Millipore) and GATA3 (1:1000, Santa-Cruz; H-48). On the
second day, the membranes were washed three times with TBST,
incubated with horseradish peroxidase-conjugated secondary antibody
(1:30000, DAKO, Ely, UK) for 1 h. The chemilluminance signals were
detected by incubating the membranes with ECL substrate (Perkin Elmer,
Seer Green, UK) and exposed to X-ray films (GE Healthcare, Amersham, UK).
RNA extraction, reverse transcription and real-time quantitative
PCR
For RNA extraction, reverse transcription and real-time quantitative PCR,
see Supplementary Materials and Methods.
Chromatin immunoprecipitation
Forty microlitres of Dynabeads Protein A/G was washed with 200 μl of TSE I
buffer for three times and diluted with 40 μl of TSE I buffer. Four
micrograms of antibodies against BRCA1 (Millipore, 07-434), EZH2
(Diagenode; C15410039), DNMT1 (Abcam; ab87656), DNMT3a (Abcam;
ab2850), DNMT3b (Abcam; ab13604), H3K27me3 (Abcam; ab6002) and
rabbit/mouse IgG negative control (DAKO) were used for each ChIP
experiment. All ChIP data were originally acquired as % of input and
further normalized with the values for IgG controls. For details, see
Supplementary Materials and Methods Quantitative real-time PCR were
performed the using primers listed in Supplementary Figure S2.
Sulforhodamine B assay
For sulforhodamine B assay, see Supplementary Materials and Methods.
Tissue microarray, immunohistochemistry and staining scoring
The tissue microarray for analysis of FOXO3 expression and BRCA mutation
status was from the Asan Medical Center, University of Ulsan College of
Medicine, Seoul, Korea. The tissue microarray contains 308 cases of breast
cancer cases including 62 cases with BRCA1 mutation, 96 cases with BRCA2
mutation and 150 cases of wild-type BRCA with patient consent. For
immunohistochemistry and staining scoring, see Supplementary Materials
and Methods. To avoid subjectivity in evaluation, staining intensity
and percentage was scored by two independent individuals in a semi-
quantitative way and the average was taken. Cytoplasm and nucleus
expression of FOXO3 and EZH2 was scored as previously described.37
Statistical analysis
Students’ t-test was used to evaluate the difference between treatment and
control group or between non-transfected samples and transfected samples.
The correlations between FOXO3 expression levels and BRCA mutation status
were studied by Mann–Whitney U-rank test in SPSS (IBM, version 17,
Portsmouth, UK). P-values o0.05 were considered statistically significant.
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